Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) suggests that ...

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) suggests that weight loss program targeting a particular % weight loss are often failing, ...

While you may think you need expensive personal trainers, nutritionists or fancy gyms to lose weight, the truth is that ...

There's nothing like throwing some punches when you need to release frustration. Here's the fear I don't want holding you back from reaping the amazing benefits of boxing.

Primary care company knownwell said on Wednesday it will provide health and weight-management services on Eli Lilly's ...

When it comes to weight loss supplements, consumer experiences and real-world results matter more than marketing hype. With ...

Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...

Shares of Hims & Hers Health (NYSE:HIMS) traded higher on Tuesday after the telehealth company announced the addition of ...

Sucralose increases hypothalamic activity linked to hunger more than sugar or water, especially in women and people with ...

We recently published a list of Billionaire Ken Fisher’s Top 13 Growth Stock Picks. In this article, we are going to take a ...

Claims data also show rapid adoption of GLP-1 for weight loss, with a steady increase in utilization since 2021 and peaking ...